{"transactions":[{"id":737703,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":38143,"kind":"person","name":"Xu Yuan","position":1,"cik":"0001858214","reported_name":"Xu Yuan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-15T20:10:18.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":87900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":87900,"derivative":{"exercise_price":2.06,"expiration_date":"2036-06-12","underlying":"Common Stock","underlying_shares":87900},"source":{"system":"sec-edgar","filing":"0001193125-26-271090","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526271090/ownership.xml","form_type":"4"}},{"id":739021,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":38143,"kind":"person","name":"Xu Yuan","position":1,"cik":"0001858214","reported_name":"Xu Yuan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-12T20:07:07.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":5000,"derivative":{"exercise_price":7.99,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001193125-26-269398","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526269398/ownership.xml","form_type":"4"}},{"id":976227,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":38143,"kind":"person","name":"Xu Yuan","position":1,"cik":"0001858214","reported_name":"Xu Yuan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:25:16.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":26000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":28.79,"expiration_date":"2031-04-22","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001193125-25-312133","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312133/ownership.xml","form_type":"4"}},{"id":976226,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":38143,"kind":"person","name":"Xu Yuan","position":1,"cik":"0001858214","reported_name":"Xu Yuan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:25:16.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":26.32,"expiration_date":"2031-06-01","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001193125-25-312133","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312133/ownership.xml","form_type":"4"}},{"id":976225,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":38143,"kind":"person","name":"Xu Yuan","position":1,"cik":"0001858214","reported_name":"Xu Yuan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:25:16.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":8.13,"expiration_date":"2032-06-02","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001193125-25-312133","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312133/ownership.xml","form_type":"4"}},{"id":976224,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":38143,"kind":"person","name":"Xu Yuan","position":1,"cik":"0001858214","reported_name":"Xu Yuan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:25:16.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":50.83,"expiration_date":"2033-06-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001193125-25-312133","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312133/ownership.xml","form_type":"4"}},{"id":976223,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":38143,"kind":"person","name":"Xu Yuan","position":1,"cik":"0001858214","reported_name":"Xu Yuan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:25:16.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":26000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":23.02,"expiration_date":"2034-06-08","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001193125-25-312133","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312133/ownership.xml","form_type":"4"}},{"id":976222,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":38143,"kind":"person","name":"Xu Yuan","position":1,"cik":"0001858214","reported_name":"Xu Yuan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-09T10:25:16.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9398,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab (\"Novo\"), and NN Invest Sub, Inc (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\"), effective as of December 9, 2025 (such date and time, the \"Effective Time\"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents restricted stock units (\"Company RSUs\") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of common stock of the Issuer (\"Company Common Stock\") upon vesting of the Company RSU."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive in respect of each such Company RSU (i) cash in an amount equal to $54.00 (the \"Closing Consideration\") and (ii) one contractual contingent value right (a \"CVR\") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement), without interest and subject to any withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-312133","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312133/ownership.xml","form_type":"4"}},{"id":1112776,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":38143,"kind":"person","name":"Xu Yuan","position":1,"cik":"0001858214","reported_name":"Xu Yuan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-12T20:35:42.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":31000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 11, 2025 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2026 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":31000,"derivative":{"exercise_price":0.693,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0001415889-25-016967","document":"form4-06122025_080636.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000141588925016967/form4-06122025_080636.xml","form_type":"4"}},{"id":1121425,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":38143,"kind":"person","name":"Xu Yuan","position":1,"cik":"0001858214","reported_name":"Xu Yuan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-05T16:05:50.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":9398,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs shall vest in full on the earlier of (i) June 3, 2026, and (ii) the next annual meeting of the Company's stockholders, subject to the director's continued service on the Board."}],"balance_after":9398,"source":{"system":"sec-edgar","filing":"0000950170-25-082308","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025082308/ownership.xml","form_type":"4"}},{"id":1129155,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":38143,"kind":"person","name":"Xu Yuan","position":1,"cik":"0001858214","reported_name":"Xu Yuan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T20:09:33.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) May 29, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":55000,"derivative":{"exercise_price":1.32,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0000950170-25-079720","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017025079720/ownership.xml","form_type":"4"}},{"id":1438723,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":38143,"kind":"person","name":"Xu Yuan","position":1,"cik":"0001858214","reported_name":"Xu Yuan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-07T20:01:01.000Z","date":"2024-08-06","kind":"sale","planned":true,"acquired":false,"shares":633,"price":4.23,"value":2677.59,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024."}],"balance_after":8669,"source":{"system":"sec-edgar","filing":"0000950170-24-092718","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017024092718/ownership.xml","form_type":"4"}},{"id":1476767,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":38143,"kind":"person","name":"Xu Yuan","position":1,"cik":"0001858214","reported_name":"Xu Yuan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-17T20:30:22.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 14, 2024 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 14, 2025 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":25000,"derivative":{"exercise_price":1.02,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-24-017210","document":"form4-06172024_040615.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000141588924017210/form4-06172024_040615.xml","form_type":"4"}},{"id":1483331,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":38143,"kind":"person","name":"Xu Yuan","position":1,"cik":"0001858214","reported_name":"Xu Yuan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-11T20:28:42.000Z","date":"2024-06-07","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) June 7, 2025 or (ii) the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":40000,"derivative":{"exercise_price":3.68,"expiration_date":"2034-06-07","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000950170-24-071947","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017024071947/ownership.xml","form_type":"4"}},{"id":1483553,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":38143,"kind":"person","name":"Xu Yuan","position":1,"cik":"0001858214","reported_name":"Xu Yuan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-11T17:31:05.000Z","date":"2024-06-08","kind":"grant","planned":false,"acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full on the earlier of (i) June 7, 2025, and (ii) the next annual meeting of the Company's stockholders, subject to the director's continued service on the Board."}],"balance_after":26000,"derivative":{"exercise_price":23.02,"expiration_date":"2034-06-07","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0000950170-24-072080","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024072080/ownership.xml","form_type":"4"}},{"id":1813766,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":38143,"kind":"person","name":"Xu Yuan","position":1,"cik":"0001858214","reported_name":"Xu Yuan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-07T20:01:00.000Z","date":"2023-08-04","kind":"sale","planned":true,"acquired":false,"shares":632,"price":3.71,"value":2344.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 24, 2023."}],"balance_after":9302,"source":{"system":"sec-edgar","filing":"0001209191-23-044768","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919123044768/doc4.xml","form_type":"4"}},{"id":1843497,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":38143,"kind":"person","name":"Xu Yuan","position":1,"cik":"0001858214","reported_name":"Xu Yuan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-27T18:00:59.000Z","date":"2023-06-23","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 23, 2024 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director."}],"balance_after":15000,"derivative":{"exercise_price":50.83,"expiration_date":"2033-06-22","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000950170-23-030224","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017023030224/ownership.xml","form_type":"4"}},{"id":1854203,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":38143,"kind":"person","name":"Xu Yuan","position":1,"cik":"0001858214","reported_name":"Xu Yuan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-15T20:05:31.000Z","date":"2023-06-14","kind":"sale","planned":true,"acquired":false,"shares":3460,"price":5.58,"value":19306.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 24, 2023."}],"balance_after":9934,"source":{"system":"sec-edgar","filing":"0001209191-23-037302","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919123037302/doc4.xml","form_type":"4"}},{"id":1856789,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":38143,"kind":"person","name":"Xu Yuan","position":1,"cik":"0001858214","reported_name":"Xu Yuan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-13T20:30:32.000Z","date":"2023-06-12","kind":"grant","planned":false,"acquired":true,"shares":13200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 12, 2023 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 12, 2024 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":13200,"derivative":{"exercise_price":2.8,"expiration_date":"2033-06-11","underlying":"Common Stock","underlying_shares":13200},"source":{"system":"sec-edgar","filing":"0001415889-23-009742","document":"form4-06132023_040625.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000141588923009742/form4-06132023_040625.xml","form_type":"4"}},{"id":1863776,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":38143,"kind":"person","name":"Xu Yuan","position":1,"cik":"0001858214","reported_name":"Xu Yuan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-07T20:15:03.000Z","date":"2023-06-06","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) June 6, 2024 or (ii) the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":40000,"derivative":{"exercise_price":5.52,"expiration_date":"2033-06-06","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-23-035066","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919123035066/doc4.xml","form_type":"4"}},{"id":2226401,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":38143,"kind":"person","name":"Xu Yuan","position":1,"cik":"0001858214","reported_name":"Xu Yuan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-17T20:30:28.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":13200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was granted on June 15, 2022 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 15, 2023 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service as a director of the Issuer through the vesting date."}],"balance_after":13200,"derivative":{"exercise_price":2.28,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":13200},"source":{"system":"sec-edgar","filing":"0001415889-22-006743","document":"form4-06172022_040606.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000141588922006743/form4-06172022_040606.xml","form_type":"4"}},{"id":2234043,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":38143,"kind":"person","name":"Xu Yuan","position":1,"cik":"0001858214","reported_name":"Xu Yuan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-13T20:44:23.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":11893,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) June 9, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":11893,"derivative":{"exercise_price":23.48,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":11893},"source":{"system":"sec-edgar","filing":"0001209191-22-036355","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919122036355/doc4.xml","form_type":"4"}},{"id":2234042,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":38143,"kind":"person","name":"Xu Yuan","position":1,"cik":"0001858214","reported_name":"Xu Yuan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-13T20:44:23.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":8650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Award of restricted stock units that vest in full on the earlier of (i) June 9, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":13394,"source":{"system":"sec-edgar","filing":"0001209191-22-036355","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919122036355/doc4.xml","form_type":"4"}},{"id":2244915,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":38143,"kind":"person","name":"Xu Yuan","position":1,"cik":"0001858214","reported_name":"Xu Yuan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-03T16:06:30.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 2, 2023 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director."}],"balance_after":15000,"derivative":{"exercise_price":8.13,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-22-020938","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000089924322020938/doc4.xml","form_type":"4"}},{"id":2440953,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":38143,"kind":"person","name":"Xu Yuan","position":1,"cik":"0001858214","reported_name":"Xu Yuan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-01-06T23:48:24.000Z","date":"2022-01-04","kind":"grant","acquired":true,"shares":26400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was granted on January 4, 2022 and will vest in three equal installments on January 4, 2023, January 4, 2024 and January 4, 2025."}],"balance_after":26400,"derivative":{"exercise_price":15.92,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":26400},"source":{"system":"sec-edgar","filing":"0001415889-22-000439","document":"form4-01062022_030116.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000141588922000439/form4-01062022_030116.xml","form_type":"4"}},{"id":2612893,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":38143,"kind":"person","name":"Xu Yuan","position":1,"cik":"0001858214","reported_name":"Xu Yuan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-05T20:04:21.000Z","date":"2021-08-03","kind":"grant","acquired":true,"shares":7501,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest in 36 monthly installments after the grant date, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date."}],"balance_after":7501,"derivative":{"exercise_price":83.25,"expiration_date":"2031-08-02","underlying":"Common Stock","underlying_shares":7501},"source":{"system":"sec-edgar","filing":"0001209191-21-049914","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919121049914/doc4.xml","form_type":"4"}},{"id":2612892,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":38143,"kind":"person","name":"Xu Yuan","position":1,"cik":"0001858214","reported_name":"Xu Yuan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-05T20:04:21.000Z","date":"2021-08-03","kind":"grant","acquired":true,"shares":4744,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were granted pursuant to a restricted stock unit award.  The units will vest in three annual installments after the grant date, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares were granted pursuant to a restricted stock unit award.  The units will vest in three annual installments after the grant date, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date."}],"balance_after":4744,"source":{"system":"sec-edgar","filing":"0001209191-21-049914","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919121049914/doc4.xml","form_type":"4"}},{"id":2683496,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":38143,"kind":"person","name":"Xu Yuan","position":1,"cik":"0001858214","reported_name":"Xu Yuan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-03T17:57:28.000Z","date":"2021-06-01","kind":"grant","acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 1, 2022 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director."}],"balance_after":13000,"derivative":{"exercise_price":26.32,"expiration_date":"2031-05-31","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001104659-21-076499","document":"tm2118278-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000110465921076499/tm2118278-5_4seq1.xml","form_type":"4"}},{"id":2739693,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":38143,"kind":"person","name":"Xu Yuan","position":1,"cik":"0001858214","reported_name":"Xu Yuan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-26T17:09:11.000Z","date":"2021-04-22","kind":"grant","acquired":false,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in 36 equal monthly installments, commencing on April 22, 2021."}],"balance_after":26000,"derivative":{"exercise_price":28.79,"expiration_date":"2031-04-22","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001104659-21-054978","document":"tm2114204-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000110465921054978/tm2114204-2_4seq1.xml","form_type":"4"}}]}